Search

everythinglearnresearchcommunity

for

Search:↓

BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Newly designed proteins can effectively degrade specific proteins in cells, offering a promising alternative for targeted protein degradation.

Partial hair-sparing brain radiotherapy is possible and doesn't affect cancer control but still causes noticeable hair loss.

The adapalene-benzoyl peroxide gel works better and faster for acne treatment than using either ingredient alone, with manageable side effects.

Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.

Sonidegib and vismodegib have different side effects and reporting patterns.

Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.

PEGylated liposomal doxorubicin improves cancer treatment effectiveness and reduces side effects like heart damage and hair loss.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Targeted anticancer therapies often cause skin issues, affecting treatment adherence and quality of life.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Botulinum neurotoxin A is effective and safe for treating various conditions, but more clinical trials are needed to fully assess its benefits and risks.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

Combining minoxidil with phototherapy improves vitiligo treatment better than phototherapy alone.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Intralesional cidofovir might be a viable alternative treatment for certain conditions.

Topical Ruxolitinib may safely treat severe hair loss.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

Minoxidil and botulinum toxin are equally effective for treating female hair loss.

The committee decided not to approve the drug due to low effectiveness and high risks.

A man had a severe allergic reaction to sulfasalazine, with symptoms improving after treatment and follow-up.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.